Key result
Modified citrus pectin attenuates cardiac injury, dysfunction, and oxidative stress in rats with diabetic cardiomyopathy.
Why the study?
Galectin-3's role in mediating high-glucose-induced cardiomyocyte injury and its potential as a therapeutic target in diabetic cardiomyopathy was investigated.
Does galectin-3 inhibition with modified citrus pectin improve cardiac injury and dysfunction in a rat model of diabetic cardiomyopathy?
Population
Sprague–Dawley rats with streptozotocin-induced diabetic cardiomyopathy
Comparison
DCM + modified citrus pectin (galectin-3 inhibitor) vs DCM vs control
Design
Randomized preclinical study
Follow-up
8 weeks
Authors
Loading...
May support galectin-3 inhibition in DCM; hypothesis-generating and should not change practice.
Does galectin-3 inhibition with modified citrus pectin improve cardiac injury and dysfunction in a rat model of diabetic cardiomyopathy?
Galectin-3 inhibition with modified citrus pectin attenuates cardiac injury and oxidative stress in a rat model of diabetic cardiomyopathy, suggesting a potential therapeutic target.
Sun et al. (2020) studied diabetic cardiomyopathy (DCM). modified citrus pectin (MCP) vs. control and DCM groups was evaluated on cardiac injury, dysfunction, and oxidative stress. Modified citrus pectin (100 mg/kg/day) attenuated cardiac injury, dysfunction, and oxidative stress in rats with streptozotocin-induced diabetic cardiomyopathy after 8 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: